• Policy
• Which P-CAB generic will come first, K-CAB or Vocinti?
• by Lee, Tak-Sun Sep 15, 2023 05:33am

• Policy
• Imfinzi recieves RSA reevals and seeks to extend reimb
• by Lee, Tak-Sun Sep 15, 2023 05:32am

• Policy
• Reevaluation difficult for Ildong and Abbott’s Lypsta
• by Lee, Tak-Sun Sep 14, 2023 06:40am

• Policy
• [Reporter's view] Focus on non-face-to-face contraceptives
• by Lee, Jeong-Hwan Sep 14, 2023 06:37am

• Policy
• Monterizine generics prepare for release in Oct
• by Lee, Tak-Sun Sep 13, 2023 05:28am

• Policy
• BT public-private council will soon resume operations
• by Lee, Jeong-Hwan Sep 13, 2023 05:28am

• Policy
• Will Enhertu pass PE evaluations for reimb in KOR?
• by Lee, Tak-Sun Sep 13, 2023 05:28am

• Policy
• Forxiga's generics, advertised for off-label indications
• by Lee, Hye-Kyung Sep 12, 2023 05:37am

• Policy
• Pfizer’s ALL drug Besponsa renews RSA in KOR
• by Lee, Tak-Sun Sep 12, 2023 05:37am

• Policy
• Vytorin generics suffer blow from reevaluations
• by Lee, Tak-Sun Sep 11, 2023 05:30am